European myocardial infarction (MI) market is estimated to grow modestly, at a CAGR of around 6.2%, during the forecast period. Rising heart patients, cohesive European healthcare policies, rising adoption of minimally invasive/non-invasive surgeries, and technological advancement in MI treatment is boosting the European MI treatment market. The European drug market is predicted to contribute highest in the growth of the MI treatment market followed by the device market due to the huge adoption of cardiology drugs, high cost of drugs, and favorable government policies. Europe region which includes UK, Spain, Germany, France, Italy, Sweden, and other EU countries have a significant number of CVD patients with heart diseases which are giving rise to the adoption of robotic surgeries and hybrid operating rooms.

Get Sample Copy of European Myocardial Infarction Market at: https://www.omrglobal.com/request-sample/european-myocardial-infarction-market

The companies which are contributing to the growth of the European myocardial infarction market include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Novartis AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Medtronic PLC, Merck KGaA, and Sanofi SA.

Eastern Europe has the highest rates for CVD, CHD, and other heart diseases which create huge demand for cardiology related surgeries in the region. Europe has a quality healthcare system; however, the surgeries and medical devices are costly. In Europe, in April 2019, Britain's heart Foundation has launched a global competition namely “The Big Bit Challenge” with the prize amounting to $39 million to propose a transformational solution to any CVD disease. Europe has a huge economic burden of lifestyle-oriented diseases such as CVD, CHD, MI treatment, stroke, and other heart diseases.

For More Information, get A full report of European Myocardial Infarction Market is available at: https://www.omrglobal.com/industry-reports/european-myocardial-infarction-market

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in January 2020, Novartis AG acquired the Medicines Company which is in aims to reduce cardiovascular disease patients by providing LDL cholesterol to the people suffering from atherosclerotic cardiovascular. This acquisition will enable the company to leverage its customers with an advanced treatment option.
Market Segmentation

European Myocardial Infarction Market by Type

• Non-ST-elevation myocardial infarction (NSTEMI)
• ST-elevation myocardial infarction (STEMI)
• Silent Heart Attacks

European Myocardial Infarction Market by Device

• Left Ventricular Assist Device (LVAD)
• Pacemaker
• Catheters
• Implantable Cardioverter-Defibrillator (ICD)
• Others (Stent Graft)

European Myocardial Infarction Market by Diagnosis

• Electrocardiography (ECG)
• Chest X-Ray
• Computed Tomography (CT Scan)
• Echocardiography
• Others (Blood Test)

European Myocardial Infarction Market by Treatment

• Medication
• Analgesics
• Thrombolytic
• Antiplatelet Agents
• Glycoprotein IIb/IIIa Inhibitors
• Others (Beta-Adrenergic Blockers)
• Surgery
• Angioplasty
• Bypass Surgery
• Heart Transplant

European Myocardial Infarction Market by End-User

• Hospital & Clinics
• Ambulatory Surgical Centers
• Research Institutes

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/european-myocardial-infarction-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404